Clinical case report where BRsM improved a patient with SLE, improving her immunomodulatory response, oxidative stress and mitochondrial dysfunction.

I present the case of a patient with SLE, with poor response to conventional treatments, and very good response to BrsM.Reviewing a bit, the literature found that systemic lupus erythematosus (SLE) is a complex, heterogeneous, systemic autoimmune disease that affects multiple organs of the human body. Its development involves a wide range of aberrant innate and adaptive immune responses. The immune microenvironment characteristic of SLE encourages metabolic reprogramming of immune cells, leading to immune dyshomeostasis that triggers autoimmune inflammation.Furthermore, the gut microbiota has emerged as a crucial element in the etiology of SLE. Dysbiosis, defined as an imbalance in the composition of the microbiome, has been linked to both the onset and progression of the disease. This imbalance exacerbates SLE symptoms by influencing systemic immunity, breaking bacterial tolerance, and enhancing inflammatory responses.Numerous recent studies have highlighted the fundamental role of oxidative stress and microbiota in the development of SLE and its comorbidities. These reactive species contribute to autoantigen and proinflammatory cytokine release, perpetuating the chronic inflammatory state associated with the disease. Current findings have identified the potential for new therapeutic approaches targeting microbiome modulation and regulation of oxidative stress, offering new perspectives for the treatment of this complex autoimmune disease.In this unique case, management with bioregulatory medicine generated a comprehensive immune, clinical and metabolic response, contributing significantly to the control of oxidative stress and the improvement of mitochondrial function, as well as its inflammatory and immunological response. This approach allowed for an excellent evolution, reflected not only in the improvement of biochemical parameters, but also in a notable reduction in the patient's symptoms.caso clínico, LUPUS, ESTRES OXIDATIVO, MITOCONDRIA, MICROBIOTA